Skip to main content

Table 2 Pre-study dopamine agonist, allocated treatment arm, first and second IMP and daily dose and duration of IMP treatments

From: Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment

Patient study code Pre-study dopamine agonist Trial arm First IMP Daily dose (mg) Number of days on IMP Second IMP Daily dose (mg) Number of days on IMP
PD1 RPR 1 PPX 2.1 3 RPRa, b 8 134
PD2 RPR 1 PPX 2.62 58 RPR 10 48
PD3 RPR 2 RPR 6 51 PPX 1.57 58
PD4 RPR 2 RPR 4 40 PPX 1.05 55
PD5 Consented but then withdrew before taking first IMP
PD6 PPX 1 PPX 2.1 64 RPR 8 52
PD7 PPX 2 RPR 10 13 PPXa, b 2.62 97
PD8 RPR 2 RPR 12 54 PPX 3.15 62
PD9 PPX 1 PPX 1.57 62 RPR 6 56
PD10 RPR 1 PPX 2.1 53 RPR 8 68
PD11 PPX 1 PPX 1.05 48 RPRb 4 30
PD12 PPX 2 RPR 10 52 PPX 2.62 56
PD13 Consented but then withdrew before taking first IMP
PD14 PPX 1 PPX 0.52 52 RPR 2 37
PD15 Consented but then withdrew before taking first IMP
PD16 PPX 1 PPX 1.57 63 RPR 6 55
PD17 PPX 2 RPR 6 60 PPX 1.57 37
PD18 PPX 2 RPR 6 3 Withdrew from IMP and study
PD19 RPR 1 PPX 2.1 55 RPR 8 84
PD20 PPX 2 RPR 8 66 PPX 2.1 41
PD21 PPX 1 PPX 3.15 100 RPRb 12 7
PD22 RPR 2 RPR 6 55 PPX 1.57 48
PD23 PPX 2 RPR 8 5 Withdrew from IMP and study
PD24 RPR 2 RPR 6 58 PPX 1.57 37
PD25 RPR 2 RPR 2 68 PPX 0.52 62
  1. PPX pramipexole PR, RPR ropinirole
  2. aWithdrew from study and reverted to pre-study dopamine agonist
  3. bDiscontinued their assigned treatment due to non-serious adverse events, reverted back to pre-study agonist but agreed to remain in study to test study processes